|
|
 |
|
Viewing report
|
|
|
|
Boehringer Ingelheim GmbH: PharmaVitae Profile
Datamonitor, Dec 2010, Pages: 73
Introduction
This analysis examines the historical and forecast performance for Boehringer Ingelheim in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.
Features and benefits
- Gain insight into Boehringer Ingelheim's strategic outlook across the next 6 years
- Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source
Highlights
Strategic insight into the prospects for Boehringer Ingelheim over the next six years.
Picking out key strengths, weaknesses, opportunities and threats and evaluating the company's prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales.
Your key questions answered
- Benchmark Boehringer Ingelheim's performance against key rivals in the prescription pharmaceutical sector
- Boehringer Ingelheim has achieved impressive historical revenue growth, but without in-licensing deals or acquisitions, its performance is set to wane
- Recently launched Pradaxa is expected to reach blockbuster status. Will this and other launches be sufficient to offset major patent expiries?
|
|
|
|
